Company research
DELCATH SYSTEMS, INC.
CIK 872912Updated Sep 24, 2026
SecurityDCTH · NASDAQ · equity
Name history
DELCATH SYSTEMS, INC. · through Aug 14, 2026DELCATH SYSTEMS INC · through Apr 22, 2013
DCTH price & chart
Loading TradingView…
NASDAQ:DCTH on TradingView ↗About the company
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.
In the news
No coverage from other publishers is available.
Recent filings
S-8 filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G filing
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by BlackRock, Inc. regarding DELCATH SYSTEMS, INC.
ARS filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 123,632,000Source | 76,589,000Source | 38,613,000Source | 17,862,000Source |
| Property, Plant and Equipment, NetUSD | 3,166,000Source | 1,790,000Source | 1,352,000Source | 1,422,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 43,454,000Source | 32,412,000Source | 12,646,000Source | 7,671,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 11,744,000Source | 10,890,000Source | 241,000Source | 366,000Source |
| Inventory, NetUSD | 10,252,000Source | 6,933,000Source | 3,322,000Source | 1,998,000Source |
| Assets, CurrentUSD | 119,530,000Source | 73,760,000Source | 37,158,000Source | 16,155,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,498,000Source | 2,704,000Source | 1,091,000Source | 1,969,000Source |
| Operating Lease, Right-of-Use AssetUSD | 936,000Source | 1,039,000Source | 103,000Source | 285,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,413,000Source | 7,843,000Source | 22,836,000Source | 23,721,000Source |
| Commitments and ContingenciesUSD | — | — | — | 0Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 347,000Source | 331,000Source | 228,000Source | 100,000Source |
| Additional Paid in CapitalUSD | 639,145,000Source | 599,881,000Source | 520,576,000Source | 451,608,000Source |
| Retained Earnings (Accumulated Deficit)USD | -528,848,000Source | -531,548,000Source | -505,162,000Source | -457,484,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 575,000Source | 82,000Source | 135,000Source | -83,000Source |
| Stockholders' Equity Attributable to ParentUSD | 111,219,000Source | 68,746,000Source | 15,777,000Source | -5,859,000Source |
| Liabilities and EquityUSD | 123,632,000Source | 76,589,000Source | 38,613,000Source | 17,862,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,950,000Source | 6,144,000Source | 16,448,000Source | 14,735,000Source |
| Operating Lease, Liability, CurrentUSD | 101,000Source | 105,000Source | 37,000Source | 186,000Source |
| Accounts Payable, CurrentUSD | 2,658,000Source | 961,000Source | 1,012,000Source | 2,018,000Source |
| Operating Lease, Liability, NoncurrentUSD | 835,000Source | 933,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 628,000Source | 766,000Source | 840,000Source | 1,144,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 8,191,000Source | 5,078,000Source | 5,249,000Source | 4,685,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | 0Source |
| Long-term DebtUSD | — | 0Source | 10,150,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 854,000Source | 10,649,000Source | -125,000Source | 322,000Source |
| Increase (Decrease) in InventoriesUSD | 3,319,000Source | 3,611,000Source | 1,324,000Source | 587,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 22,516,000Source | -18,681,000Source | -31,251,000Source | -24,950,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -26,590,000Source | -981,000Source | -19,709,000Source | -209,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,547,000Source | 559,000Source | 58,000Source | 209,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 6,000,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 15,048,000Source | 39,410,000Source | 51,778,000Source | 10,143,000Source |
| Repayments of Long-term DebtUSD | — | 10,600,000Source | 6,313,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 11,042,000Source | 19,716,000Source | 874,000Source | -15,131,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 43,500,000Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 1,236,000Source | 1,459,000Source | 1,873,000Source |
| Income Taxes Paid, NetUSD | 1,545,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 24,232,000Source | 9,767,000Source | 8,151,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | 0Source | 460,000Source | 776,000Source | 768,000Source |
| DepreciationUSD | 238,000Source | 134,000Source | 128,000Source | 132,000Source |
| Income Tax Expense (Benefit)USD | 810,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | 2,700,000Source | -26,386,000Source | -47,678,000Source | -36,508,000Source |
| Operating ExpensesUSD | 72,774,000Source | 43,427,000Source | 39,612,000Source | 35,886,000Source |
| Operating Lease, ExpenseUSD | 200,000Source | 200,000Source | — | — |
| Other Nonoperating Income (Expense)USD | -70,000Source | -30,000Source | -59,000Source | 30,000Source |
| Payments to Acquire InvestmentsUSD | 93,216,000Source | 52,453,000Source | 19,651,000Source | — |
| Proceeds from Issuance of Common StockUSD | 481,000Source | 250,000Source | 123,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 4,409,000Source | 1,682,000Source | 4,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 85,231,000Source | 37,205,000Source | 2,065,000Source | 2,719,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 43,528,000Source | 29,553,000Source | 22,110,000Source | 17,303,000Source |
| Operating Income (Loss)USD | 660,000Source | -12,410,000Source | -38,182,000Source | -33,853,000Source |
| Other Nonoperating Income (Expense)USD | -70,000Source | -30,000Source | -59,000Source | 30,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 3,510,000Source | -26,386,000Source | -47,678,000Source | -36,507,000Source |
| Income Tax Expense (Benefit)USD | 810,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | 2,700,000Source | -26,386,000Source | -47,678,000Source | -36,508,000Source |
| Earnings Per Share, BasicUSD per share | 0.08Source | -0.93Source | -2.94Source | -4.12Source |
| Earnings Per Share, DilutedUSD per share | 0.07Source | -0.93Source | -2.94Source | -4.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 35,821,157Source | 28,511,393Source | 16,229,931Source | 8,864,615Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 39,919,557Source | 28,511,393Source | 16,229,931Source | 8,864,615Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 810,000Source | — | — | — |
| Gross ProfitUSD | 73,434,000Source | 31,017,000Source | 1,430,000Source | 2,033,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 2,720,000Source | -26,806,000Source | -41,303,000Source | -34,547,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 2,920,000Source | 125,000Source | -1,439,000Source | -2,685,000Source |
| Operating ExpensesUSD | 72,774,000Source | 43,427,000Source | 39,612,000Source | 35,886,000Source |
| Operating Lease, ExpenseUSD | 200,000Source | 200,000Source | — | — |
| Research and Development ExpenseUSD | 29,246,000Source | 13,874,000Source | 17,502,000Source | 18,583,000Source |
Filing attachments
dcth-q22026erex991.htm · 8-K · 2026-08-06
EX-99.1 2 dcth-q22026erex991.htm EX-99.1 Document Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY - August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the seco…
Read attachment ↗dcth-q126erex991.htm · 8-K · 2026-05-07
EX-99.1 2 dcth-q126erex991.htm EX-99.1 Document Exhibit 99.1 Delcath Systems Reports First Quarter 2026 Results and Business Highlights 2026 Revenue Guidance of at least $100M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY - May 7, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2…
Read attachment ↗d16781dex991.htm · 8-K · 2026-03-03
EX-99.1 2 d16781dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology Publication Highlights Promise of Combined Percutaneous Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma QUEENSBURY, NY - March 3, 2026 Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the …
Read attachment ↗dcth-q425erex991.htm · 8-K · 2026-02-26
EX-99.1 2 dcth-q425erex991.htm EX-99.1 Document Exhibit 99.1 Delcath Systems Reports Fourth Quarter and Full Year 2025 Results Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY - February 26, 2026, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended Decem…
Read attachment ↗d52022dex991.htm · 8-K · 2026-01-12
EX-99.1 2 d52022dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results QUEENSBURY, NY - January 9, 2026, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025. Preliminary F…
Read attachment ↗d52022dex992.htm · 8-K · 2026-01-12
EX-99.2 3 d52022dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Corporate Presentation NASDAQ: DCTH January 9, 2026 Forward-Looking Statement alternative indications; the impact of the COVID-19 pandemic or other pandemics on the The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward- completion of our clinical trials; the impact of the presentations at major medical looking statements made by the Company or on its behalf. This presentation contains conferences and …
Read attachment ↗